AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition
Executive SummaryAlong with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.
You may also be interested in...
Terns raised an $80m Series B round for NASH and cancer programs, while 89Bio launched with a $60m Series A to fund drugs for NASH and other liver and metabolic diseases. Also, Stoke leads recent VC deals with $90m Series B.
Duo to equally share development costs and profits from any candidates emerging from their RNAi discovery pact.